New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
08:34 EDTIMMUImmunomedics announces U.S. patent for IMMU-144
Immunomedics announced the issuance of U.S. patent no. 8,722,047 for the company's patent application "Humanized anti-HLA-DR antibodies," with an expiration date of May 26, 2026. The new patent concerns compositions of humanized anti-HLA-DR antibodies of use for disease therapy. The allowed claims protect IMMU-114, which is being investigated as a monotherapy in a newly-opened Phase I dose-escalation trial in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
14:34 EDTIMMUImmunomedics presents updated results with sacituzumab govitecan in lung cancer
Immunomedics announced that 33% of patients with small cell lung cancer, SCLC, and 31% with non-small cell lung cancer, NSCLC, had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, ADC. Including patients that reported stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed. Dr. Francois Wilhelm, Chief Medical Officer, presented the updated results at the 15th Annual Targeted Therapies of Lung Cancer Meeting, an invitation-only meeting sponsored by The International Association for the Study of Lung Cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use